cGxP.wire https://validator.w3.org/feed/docs/rss2.html Avalyn Pharma Presents New AP01 Data in Pulmonary Fibrosis CONNECTA Therapeutics Secures €3.1M for Fragile X Program Teitur Trophics Advances TT-P34 Toward Phase II in Parkinson’s EPIK Biosciences Expands Ketamine and DXM Drug Portfolio Disc Medicine Advances DISC-3405 in Polycythemia Vera BioLineRx and Hemispherian Present GLIX1 Data Roche Wins FDA Priority Review for Enspryng in MOGAD Compass Pathways Advances COMP360 Toward Potential TRD Launch GSK Shingrix Prefilled Syringe Approved in Japan Insilico Doses First Patient in AI-Driven Phase 3 IPF Trial Schrödinger Launches Tectora With $55 Million Series A IDEAYA and Servier Launch Phase 3 Uveal Melanoma Trial Tyra Reports Phase 2 Dabogratinib Results in Bladder Cancer Seaport Therapeutics Advances GlyphAllo in Major Depression Marengo Completes STARt-001 Enrollment, Strengthens Team Bayer Advances GIRK4 Inhibitor Into Phase II for Atrial Fibrillation Harbour BioMed Partner Solstice Oncology Raises $225M Cocrystal Pharma Advances CDI-988 in Norovirus Challenge Study Beeline Medicines Advances Afimetoran Toward Pivotal Lupus Trials MetaVia Reports Preclinical Data on DA-1726 Waist Reduction Kazia Doses First Patient in Pediatric AT/RT Study Can-Fite Reports Namodenoson Liver Cirrhosis Case Kura Oncology launches Caspian Therapeutics with $50M financing BioMarin Reports Positive Phase 3 VOXZOGO Data AEYE-DS Data Show 99% Imageability in Eye Screening Emboline Receives FDA 510(k) Clearance for Emboliner Rezolute Awaits FDA Review of Ersodetug in Congenital HI Leyden Labs Advances RIG-101 Toward Phase 2 in Asthma UCB Wins FDA Breakthrough Therapy Designation for CIMZIA Eir Partners Acquires Accumulus to Scale Life Sciences Fate Therapeutics Presents FT819 Clinical Data at CCR-West 2026 Nanoscope’s MOGENRY BLA Accepted by FDA for Retinitis Pigmentosa MannKind and Rose Pharma Partner on Inhaled GLP-1 Opus Genetics Advances OPGx-BEST1 Toward Phase 3 Context Therapeutics Doses First Patient in CT-202 Phase 1 Evommune Reports Phase 2b Setback for EVO756 in Atopic Dermatitis Revvity to Acquire Human Cell Design for Metabolic Drug Discovery Pyxis Oncology Advances MICVO Toward Phase 3 in HNSCC Adagene and Exelixis Advance SAFEbody ADC Programs LUMA Vision Wins FDA Clearance for VERAFEYE Cardiac Platform LabCentral Launches The Loop for Global Biotech Startups Quoin Pharmaceuticals Gains FDA Pediatric Designation for QRX003 Scinai Refocuses NanoAb Platform and CDMO Growth CAMP4 Therapeutics Prepares CMP-002 Phase 1/2 Trial for SYNGAP1 BridgeBio Advances Oral Infigratinib Toward Achondroplasia Launch Orphalan Launches Phase 3 Trial of Once-Daily Trientine Spyre Therapeutics Advances SPY003 in UC with Positive Phase 2 Data Labcorp Acquires MLM to Expand Global Clinical Trial Labs CraniUS Wins FDA 510(k) Clearance for Cranial Implant Callio Therapeutics Names Zachary Hornby as CEO